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Purpose: Evaluate the efficacy of norethindrone acetate in the resolution of symptoms and 
regression of recurrent endometrioma.
Patients and methods: Retrospective chart review at SUNY Downstate Medical Center of 
patients with a history of surgical excision of endometrioma (with histological confirmation) and 
recurrent endometrioma (demonstrated by strict sonographic criterion of endometrioma) who 
were willing to undergo follow-up. Patients were prescribed norethindrone acetate to be taken 
daily with follow-up sonograms until cysts regressed. Statistical analysis included Student’s t-test 
and a simple linear regression model to assess cyst regression over time during treatment.
Results: Degree of pain was significantly lower on treatment when compared to baseline 
(P , 0.00001). Cyst size was significantly smaller in as little as 3 months (P , 0.0001). Average 
rate of regression with continuous treatment was 0.025 ± 0.015 cm/day. Total mean ± standard 
deviation regression time is 10.28 ± 8.25 months.
Conclusion: Norethindrone acetate was effective in eradicating symptoms and producing 
complete regression of recurrent endometriomas. It should be considered for patients who 
are likely to adhere to a prolonged treatment regimen and comply with recommendations for 
surveillance with serial sonograms.
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Introduction
Endometriosis is one of the most challenging gynecological disorders of our era1 that 
occurs in women of reproductive age. According to the National Institute of Health, 
approximately 5.5 million women in North America have endometriosis.2 It is found 
in 2%–22% of asymptomatic women,3–6 40%–60% of patients with dysmenorrhea, and in 
20%–30% of women with primary infertility.7,8 A common form of endometriosis is an 
ovarian endometrioma, occurring in 17%–44% of women who have endometriosis.4,7,12,13 
Norethindrone acetate (NA) has been established as an effective long-term treatment 
for endometriosis because it produces a hypoestrogenic, acyclic hormonal environment 
by suppressing gonadotropins, inhibiting ovulation, and developing amenorrhea with 
eventual decidualization and atrophy of endometrial tissue.9–11
A recurring endometriotic ovarian cyst is often of concern and frequently a cause of 
repeated surgical and medical intervention. Laparoscopic resection has been   proposed 
as the gold standard of treatment for endometriomas and related symptoms.14–18 
  However, there is a relatively high recurrence rate of endometriomas (12%–30% after 
2–5 years of follow-up),19–25 which were treated primarily with conservative   surgical 
management.26 This rate may be underestimated as it does not take into account patients 
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who have recurrent cysts but are asymptomatic and do not 
seek further testing or treatment. Furthermore, few studies 
have shown the effect of pure medical therapy on endometri-
omas and some have found that medical treatment alone is 
inadequate.27,28 Specifically, Donnez et al suggested that 
endometriomas equal to or larger than 3 cm do not respond 
well to medical therapy.29
The management of recurrent endometriomas and the 
efficacy of a second surgery and its associated symptoms 
have only been explored in a few studies.23,30–33 Efforts to 
surgically extirpate this lesion and preserve ovarian func-
tion have had mixed results. Laparoscopic techniques for 
the excision of endometrioma, in particular the stripping 
technique, have been controversial because they may 
result in excessive loss of normal ovarian tissue.26 Recent 
studies have suggested that the stripping of endometrioma 
may induce loss of follicle reserves and may decrease the 
number of oocytes retrieved during in vitro fertilization 
cycles.18,19,23,26 These findings suggest that the surgical 
removal of a recurrent endometrioma is best avoided if 
preservation of ovarian function is paramount.26   Supporting 
this view is data published showing an elevated risk for 
premature ovarian failure following resection of bilateral 
endometriomas.34,35 Additionally, when endometriomas 
recur, they present an even greater surgical challenge due 
to the formation of postsurgical adhesions in conjunction 
with the underlying intense chronic inflammatory process 
associated with endometriosis. Despite the general dissat-
isfaction with surgical treatment for endometriomas, few 
studies have examined the efficacy of medical therapy in this 
clinical context.14,31 In support of the theory that progesterone 
therapy may reduce recurrence rates are studies which show 
that pregnancy, a condition characterized by tonic elevations 
of serum progesterone, is protective in patients with prior 
resection of endometriomas.24
Studies examining the efficacy of medical therapy for 
recurrent endometriomas have thus far evaluated gonadotro-
pin-releasing hormone (GnRH) agonists, danazol, aromatase 
inhibitors, and oral contraceptive pills.25,28,36-40 However, all 
of these studies, with the exception of Seal et al36 have solely 
focused on preventing, rather than treating, a recurrence. 
Seal et al36 showed the effect of aromatase inhibitors on treat-
ing   recurrent endometriomas. However, a major limitation 
was that the authors evaluated the effectiveness of aromatase 
inhibitors in only five subjects.
To our knowledge, no studies have been conducted that 
evaluate the efficacy of NA in effecting resolution of symp-
toms and regression of recurrent endometriomas. In this 
retrospective review we aim to evaluate NA in achieving 
these clinical outcomes.
Material and methods
A retrospective chart review was conducted at Downstate 
Medical Center’s Reproductive Endocrinology and Infertility 
Clinic with approval from the Institutional Review Board. 
Women that underwent laparotomy or laparoscopic removal 
of ovarian endometrioma, had symptomatic endometri-
omas (defined by the presence of pelvic pain and abnormal 
  bleeding), and were taking NA were included in this review. 
The presence of a recurrent endometrioma (unilateral or 
bilateral) was defined as the sonographic evidence of a 
round, homogenous, hypoechoic, low-level echo cyst, or 
thin internal heterogenous trabeculation (with or without 
internal septa), absence of, or poor vascularity of capsule, 
and septa.41 Women who had adnexal masses with solid 
components and/or desired immediate childbearing were 
excluded from this review. Twenty-one patients met our 
inclusion criteria.
All patients were initially prescribed 5 mg of NA. The 
dose was increased by 2.5 mg according to the patient’s 
response until amenorrhea was achieved. A pelvic sonogram 
was performed prior to starting treatment and all partici-
pants were re-evaluated at 3 month intervals. Clinical and 
demographic data including age, parity, weight, symptoms, 
medical treatment compliance, and sonogram findings were 
recorded. Dysmenorrhea was evaluated by visual analog 
scale (VAS), with 0 representing no pain and 10 representing 
the worst imaginable pain. The following parameters were 
retrospectively analyzed in follow-up visits: dysmenor-
rhea by VAS, presence of breakthrough bleeding, weight 
changes, and serial pelvic sonograms for endometrioma 
cyst   dimensions. A simple linear regression model was con-
structed to assess cyst regression over time during treatment. 
Resistant methods were utilized to fit the models.
Results
Twenty-one patients met our inclusion criteria. However, 
three patients (P1, P2, P3) were excluded from analysis. 
P1 had high follicle-stimulating hormone and luteinizing 
hormone levels. Thus, the decrease in endometrioma size 
may have been attributable to menopause. P2 and P3 had 
questionable compliance due to frequent and long interna-
tional travel between visits and sonograms. Additionally, 
their dosage schedule differed from all other patients in this 
review. However, all three of these patients had significant 
cyst regression while on NA.
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Demographics
Eighteen patients were assessed in this review. The patient 
characteristics and demographics are summarized in Table 1. 
Comprising the 18 patients, twelve underwent a laparoscopy 
while six had a laparotomy and 14 patients had a unilateral 
endometrioma while four had bilateral endometriomas. We 
compared subjects on surgery type, endometrioma location, 
and age and examined their effect on response rate between 
the two groups (completed versus on treatment) and found 
no significant effect.
Pain
Pain scores were rated using VAS where 10 represents 
the worst imaginable pain. Sixteen (88.89%) of patients 
reported complete resolution (100%) of dysmenorrhea on 
treatment, with two (11.11%) patients only experiencing 
mild discomfort (a pain grade of 3 or lower) at their last 
visit. The clinical outcomes for pain (Figure 1) in our 
patient population are presented in quartiles. Length of 
treatment ranged from just under 3 months to 33 months 
and thus quartile scores were retrospectively composed 
based on the individual patient’s length of treatment. The 
averages across all subjects for each quartile are reported. 
All subjects had a baseline and final score. Two subjects 
had two missing values and one subject had three miss-
ing values due to a treatment time ranging from less than 
3 months to 6 months and thus requiring fewer intermediary 
visits. One additional subject had two missing values due 
to having only three visits in her 1-year treatment length. 
These missing values were dropped and not included in 
the averages. The degree of pain was found to be signifi-
cantly lower at all intervals when compared to baseline 
(P , 0.00001).
Cyst size
A simple linear regression model was constructed to assess 
cyst regression over time during treatment. Resistant meth-
ods were utilized to fit the models. Fourteen patients had 
complete regression and four patients are currently receiv-
ing treatment. For patients currently on treatment, their 
regression rates were projected into the future based upon 
their current rate of regression from previous visits. Total 
across both groups, baseline cyst size for all patients was 
6.46 ± 3.92 cm and the average dose was 5 mg of NA taken 
orally at bedtime. The average rate of regression (mean ± 
SD) with continuous treatment was 0.025 ± 0.015 cm/day 
and average length of treatment was 10.28 ± 8.25 months. 
Individuals currently on treatment had significantly higher 
cyst size (11.23 cm ± 5.92 cm vs 4.47 cm ± 1.90 cm; 
P = 0.0013) thus resulting in significantly more months 
necessary for complete regression (20.01 ± 10.66 vs 7.47 
± 4.52; P = 0.0012). The rate of regression did not differ 
between the two groups. Figure 2 shows the average trend 
of cyst regression across 3 month intervals. Using Student’s 
t-test, all intervals were significantly lower compared to 
baseline (P , 0.0001).
Side effects
A frequent side effect of NA is breakthrough bleeding. 
Breakthrough bleeding was reported by eight (44.44%) of 
Table 1 Patient demographics (mean ± standard deviation) by completion status (n = 18)
Complete Incomplete P-valuea
Age (years) 35.1 ± 8.6 35.2 ± 8.5 Ns
Age at menarche (years) 12.9 ± 1.4 13.3 ± 1.7 Ns
Weight (kg) 76.9 ± 22.22 76.5 ± 22.1 Ns
Treatment time (months) 7.5 ± 7.5 20.1 ± 10.66 0.0012
Maximum cyst size (cm) 4.47 ± 1.9 11.23 ± 5.92 0.0013
Rate of regression (cm/day) 0.026 ± 0.017 0.02 ± 0.011 Ns
Endometrioma location 
  Unilateral 
  Bilateral
 
11 
3
 
3 
1
Type of surgery 
  Laparoscopy 
  Laparotomy
 
11 
3
 
1 
3
Rate of regression (cm) 
  Unilateral vs bilateral 
  Laparoscopy vs laparotomy
 
0.028 ± 0.018 vs 0.021 ± 0.015 
0.029 ± 0.02 vs 0.019 ± 0.007
 
0.02 ± 0.006 vs 0.019 ± 0.0 
0.023 ± 0.00 vs 0.018 ± 0.005
 
Nsb
Change in weight with treatment (kg) 2.4 ± 3.9 0.8 ± 1.3 Ns
Notes: aAnalysis performed for all using Student’s t-test; bStudent’s t-test and chi-square test.
Abbreviation: Ns, Not significant.
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18 patients but was tolerated, caused no discontinuations, 
and was remedied by increasing the dose by 2.5 mg until 
resolved. Additionally, 15 (83.33%) of 18 patients reported 
weight gain (presented in Table 1).
Discussion
Our most important findings were that long-term therapy with 
NA for patients with recurrent endometrioma was effective in 
eradicating symptoms and in producing complete regression 
of the lesion in individuals that continued treatment. Given 
that surgical interventions in similar patient populations have 
had limited success, the medical management described 
may be a promising noninvasive alternative. The results of 
our treatment are very promising. There was a significant 
difference in as little as 3 months for cyst size, bleeding, and 
pain. All patients had complete resolution of bleeding, and 
the average pain score was 0.25 at the end of their treatment. 
Due to this positive effect on pain and bleeding, many of our 
patients continued treatment in order to prevent another recur-
rence and avoid surgery at the conclusion of their course.
Studies on the use of GnRH agonists, and oral 
contraceptive pills for less than 6 months or 12 months, 
respectively, were found to be ineffective in treating 
endometriomas.25,38,39 Research shows that a 3-month 
course of a GnRH agonist or danazol had no impact on 
pelvic pain in women with stage III/IV endometriosis thus 
requiring a course of 6 months or more.37,39,42 Treatment 
with aromatase inhibitors by Seal et al only reduced pelvic 
pain from severe (grades 8–10) to moderate (grades 3–4.5) 
for 80% of subjects and mild (below grade 3) for 20%.36 
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Figure 1 Pain score (mean ± standard deviation) was measured by visual analog scale (VAS) from 0–10 with “0” being no pain and “10” the worst imaginable pain.
Note: All intervals were significantly lower when compared to baseline (P , 0.00001).
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Figure 2 The average cyst size (mean ± standard deviation) at 3-month intervals.
Note: Student’s t-test shows that all intervals are significantly smaller compared to baseline (P , 0.0001).
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Our findings showed that NA resulted in significant regres-
sion of the cysts and reduction in pain scores from severe 
to mild for 100% of our patients in as little as 3 months. 
Furthermore, subjects from the Seal et al study had taken 
oral contraceptive pills, calcium, and vitamin D in order to 
prevent bone loss. Comparatively, NA is commonly used as 
add-back therapy, is well tolerated with lesser estrogenic 
side effects than oral contraceptives, and milder androgenic 
side effects than danazol. These findings may have implica-
tions for patients as they may be relieved of the pain and 
discomfort in a shorter period of time, and therefore may 
be an alternative to invasive surgery.
Several strengths of this study warrant mentioning. The 
histopathologic diagnosis of endometrioma was a criterion 
for inclusion. As such, all participants in the study shared 
a definitive diagnosis. This is in contrast to other research 
where the diagnosis of endometrioma was presumptive as it 
was based upon imaging studies.
Since the study was designed to evaluate patients treated 
with noninvasive therapy, the diagnosis of recurrence was 
predicated upon clinical suspicion and radiologic correlation. 
Recognizing this potential weakness, strict adherence to 
the radiologic determinants of recurrent endometrioma was 
applied in all cases, thereby maximizing the likelihood that 
the diagnosis in each case was correct.
Finally, all patients were similar demographically.
Some shortcomings of this study are also worth list-
ing. We had a small sample size of 18 patients. However, 
all of our findings had a P-value of ,0.0001 or better and 
all subjects had a consistent rate of regression. Secondly, 
a control group was not included for comparison, so the 
response to treatment could not be compared to no treat-
ment, and as such, the clinical improvements seen in the 
women treated may simply be the natural course of the 
disease rather than therapeutic effect. However, spontane-
ous regression of endometrioma has not been the clinical 
course most commonly observed in longitudinal studies. 
It is unlikely that all, or even most, would have resolved 
without intervention. As such, in our estimate, the lack 
of a control group does not significantly invalidate our 
findings. Additionally, since the majority of patients con-
tinued treatment after cyst regression and this study is a 
retrospective chart review, follow-up recurrence rate could 
not be evaluated.
There is still no consensus on what is the most appropri-
ate therapy for patients with recurrence of endometrioma. 
Few studies focus on the management of recurrent endo-
metrioma or the efficacy of surgical management.30,33 Those 
that have done so report suboptimal outcomes in patients 
who are treated surgically. Despite general dissatisfaction 
with surgical treatment of endometriomas, only one study 
has focused on sole medical management for the recurrence 
of this condition.
Much work remains to be done before a working 
understanding of recurrent endometrioma is established. 
Specifically, there are no known risk factors and the natural 
course of the condition is unknown. As the diagnosis of 
recurrence is dependent upon the manifestation, and indeed 
the reporting, of symptoms, the prevalence of the condition 
is also unknown. Similarly, once the diagnosis of recurrent 
endometrioma is made, the most effective therapy has not 
been established. We recommend prospective studies on 
long-term treatment and follow-up with NA as well as other 
progestins for comparison.
Conclusion
Our study supports NA as an effective treatment for this 
condition. As no gold standard for treatment exists, we rec-
ommend treatment with NA as the primary modality with 
close follow-up for 2 years or until resolution of symptoms 
is observed. Surgical intervention should be considered only 
after medical management has failed.
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